The global liver cirrhosis therapeutics market is forecast to grow at a CAGR of 4.36% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.
The report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- F Hoffman La-Roche
- Gilead Sciences
- Johnson & Johnson
- Bristol-Myers Squibb
- Conatus Pharmaceuticals
- Gwo Xi Stem Cell Applied Technology
- Instituto Grifols
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Salix Pharmaceuticals
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Market segmentation by type of molecule
PART 09: Market segmentation by types of liver cirrhosis
PART 10: Market segmentation by types of liver cirrhosis treatment
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Appendix
PART 19: About the Author
For more information visit http://www.researchandmarkets.com/research/mv46f8/global_liver